1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. Summary
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
Delayed Hong Kong Stock Exchange  -  11:59 2022-08-09 pm EDT
4.370 HKD   -3.53%
07/28Sino Biopharmaceutical CEO Resigns
MT
07/27Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022
CI
07/27Sino Biopharmaceutical Limited Announces Resignation of Li Yi as Executive Director
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
08/03/2022 08/04/2022 08/05/2022 08/08/2022 08/09/2022 Date
4.3(c) 4.41(c) 4.51(c) 4.46(c) 4.53(c) Last
24 366 953 41 351 698 28 817 823 22 032 544 28 498 592 Volume
-0.46% +2.56% +2.27% -1.11% +1.57% Change
More quotes
Estimated financial data (e)
Sales 2022 30 425 M 4 506 M 4 506 M
Net income 2022 5 060 M 749 M 749 M
Net cash position 2022 7 147 M 1 058 M 1 058 M
P/E ratio 2022 14,3x
Yield 2022 1,48%
Sales 2023 34 556 M 5 117 M 5 117 M
Net income 2023 4 850 M 718 M 718 M
Net cash position 2023 15 820 M 2 343 M 2 343 M
P/E ratio 2023 15,2x
Yield 2023 1,49%
Capitalization 72 771 M 10 777 M 10 777 M
EV / Sales 2022 2,16x
EV / Sales 2023 1,65x
Nbr of Employees 25 579
Free-Float 52,1%
More Financials
Company
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%). 
Sector
Pharmaceuticals
Calendar
08/23Earnings Release
More about the company
Ratings of Sino Biopharmaceutical Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about SINO BIOPHARMACEUTICAL LIMITED
07/28Sino Biopharmaceutical CEO Resigns
MT
07/27Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022
CI
07/27Sino Biopharmaceutical Limited Announces Resignation of Li Yi as Executive Director
CI
07/07Generon Corporation Ltd. announced that it has received $70.000203 million in funding f..
CI
06/30Hong Kong Hang Seng Down 0.6% As Tech Issues Weaken
MT
06/26Sino Biopharmaceutical Submits Application for Marketing of Anti-Tumor Capsule
MT
06/26Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-T..
CI
06/24Sino Biopharmaceutical to Buy Nasdaq-listed F-Star Therapeutics for $161 Million; Share..
MT
06/23SECTOR UPDATE : Health Care Stocks Lead Thursday Markets Recovery
MT
06/23SECTOR UPDATE : Health Care Stocks Again Outpacing Other Sectors to the Upside
MT
06/23SECTOR UPDATE : Health Care
MT
06/23SECTOR UPDATE : Health Care Stocks Edge Higher Pre-Bell Thursday
MT
06/23SECTOR UPDATE : Health Care
MT
06/23F-star Therapeutics Shares Soar on Buyout Deal
DJ
06/23Sino Biopharmaceutical Unit to Buy F-star Therapeutics for $161 Million
DJ
More news
News in other languages on SINO BIOPHARMACEUTICAL LIMITED
07/27Sino Biopharmaceutical Limited annonce des changements de PDG, à compter du 28 juillet ..
07/27Sino Biopharmaceutical Limited annonce la démission de Li Yi en tant que directeur exéc..
06/30Le Hang Seng de Hong Kong en baisse de 0,6 % en raison de l'affaiblissement des valeurs..
06/26Sino Biopharmaceutical soumet une demande de commercialisation d'une gélule anti-tumora..
06/26Sino Biopharmaceutical Limited annonce une demande de commercialisation du médicament i..
More news
Analyst Recommendations on SINO BIOPHARMACEUTICAL LIMITED
More recommendations
Chart SINO BIOPHARMACEUTICAL LIMITED
Duration : Period :
Sino Biopharmaceutical Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINO BIOPHARMACEUTICAL LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 3,90 CNY
Average target price 6,67 CNY
Spread / Average Target 71,1%
EPS Revisions
Managers and Directors
S Y Tse Chief Executive Officer & Executive Director
Jia yin Ma Group Chief Financial Officer
Theresa Tse Chairman
Zheng Fei Lu Independent Non-Executive Director
Da Kui Li Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SINO BIOPHARMACEUTICAL LIMITED-18.32%10 610
JOHNSON & JOHNSON0.02%447 486
ELI LILLY AND COMPANY9.51%287 428
PFIZER, INC.-16.56%278 132
ROCHE HOLDING AG-16.68%273 741
ABBVIE INC.1.95%248 135